HealthTree Logo
search more_vert
close
person Sign In / Create Account
Donating to Myeloma Cures: Giving Tuesday 2023
Posted: Nov 27, 2023
Donating to Myeloma Cures: Giving Tuesday 2023 image

GivingTuesday was created in 2012 as a simple idea: a day encouraging people to do good. Over the past 11 years, it's flourished into a day of online giving for those who feel gratitude and want to give back. 

Our HealthTree Community is full of people willing to dedicate their time, energy, funds, and other assets to drive more accessible myeloma education, grow a stronger community, and, perhaps most importantly, provide a way for myeloma cures. 

Hear from HealthTree Foundation founder and director Jenny Ahlstrom as she shares her thanks with our community, as well as why your donation matters to myeloma research projects and where it will go when you give to our organization this Giving Tuesday. 

I Want To Donate

Our unique model provides you with a way to accelerate myeloma cures through key myeloma research. This research allows each unique myeloma patient an opportunity to find a longer, better quality of life. 

Researchers have unique opportunities to partner with us and use anonymized data from our community to make important findings in the myeloma field. 

To date, we've collaborated with 76 investigators at 16 cancer institutions and posted 49 surveys with 64,793 patients participating. Your support this Giving Tuesday will only help these numbers multiply so we can accelerate this research and improve findings. Learn more about past research we've completed with your help here: HealthTree Research

By donating to research, you are contributing to current research projects being done with the HealthTree Foundation, such as: 

Personalizing Treatment Strategies Based On Multiple Myeloma Patient Genetics at Diagnosis 

Support our project to revolutionize multiple myeloma treatment! Led by Dr. Ola Landgren, our study aims to personalize treatment strategies based on the unique genetics of each patient at the time of diagnosis. By analyzing stored bone marrow samples and clinical data, we seek to define biological subtypes, predict prognosis, and improve clinical outcomes.

Your contribution will help us advance this groundbreaking research, potentially leading to more effective and safer personalized treatments for individuals with multiple myeloma.

This study is IRB-approved and getting ready to begin. Our myeloma community will start enrolling in Quarter 1 of 2024. 

Eye Health and Multiple Myeloma

Support groundbreaking research on eye health in multiple myeloma (MM) patients! Led by Dr. Rahul Banerjee, MD, FACP with the University of Washington, this cross-sectional study aims to understand ocular comorbidities and preventive care behaviors in individuals with MM, Monoclonal Gammopathy of Uncertain Significance (MGUS), or Smoldering Multiple Myeloma (SMM).

By contributing to this research, you can help estimate the prevalence of eye conditions, explore associations with medications, and ultimately improve the quality of life for MM patients. Your donation will make a meaningful impact on advancing knowledge and care for those affected by these conditions.
 

This study is ongoing, and you can participate today by visiting this link: Eye Health Survey 

Published research on these studies can be found here: HealthTree Research

Myeloma 3-Year Bispecific Antibody Study 

Support our 3-year Bispecific Antibody Study for multiple myeloma patients! Bispecific antibody treatment represents a groundbreaking approach, demonstrating high efficacy even as a single agent. Your donation will contribute to this observational study, gathering real-world evidence and patient-reported outcomes to address crucial questions about bispecific antibody experiences, including treatment sequencing, healthcare settings, dosing models, side effects, and impacts on quality of life.

By supporting this research, you're vital to advancing knowledge and improving the care and outcomes for individuals with relapsed/refractory myeloma. 

This study design with top myeloma investigators is currently in progress, and patients will be invited to participate in Quarter 2 of 2024. 

If you are passionate about creating a myeloma cure for everyone, donate to the HealthTree Foundation this Giving Tuesday and share with your family and friends so they can do the same. 

I Want To Donate

The author Audrey Burton-Bethke

about the author
Audrey Burton-Bethke

Audrey is the Editor for the HealthTree Foundation for Multiple Myeloma. She originally joined the HealthTree Foundation in 2020 as the Myeloma Community Program Director. While not knowing much about myeloma initially, she worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys iced chais from Dutch Bros. She also loves spending time with her supportive husband and energetic three-year-old. 

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook twitter